Royalty Pharma plc 8-K

What Happened Royalty Pharma plc (RPRX) filed an 8-K reporting that on December 20, 2025 George W. Lloyd (age 66) informed the company he will transition from his role as Executive Vice President and Chief Legal Officer effective December 31, 2025 and will remain employed as a senior advisor. Arthur R. McGivern (age 50), currently Executive Vice President and General Counsel, will assume Mr. Lloyd’s responsibilities effective January 1, 2026. Mr. McGivern joined Royalty Pharma in October 2022 and was previously a partner at Goodwin Procter LLP.

Key Details

• Change notified: December 20, 2025; Lloyd’s role change effective December 31, 2025; McGivern assumes duties January 1, 2026.
• Employment paperwork: the Executive Offer Letter dated May 16, 2025 between the company and Mr. Lloyd will be terminated effective December 31, 2025; Mr. Lloyd will move to the company’s standard form employee offer letter effective January 1, 2026.
• Successor credentials: Arthur R. McGivern has served as the company’s General Counsel since October 2022 and was a former partner at Goodwin Procter LLP.

Why It Matters This is an internal leadership transition in the company’s legal function that preserves continuity: the outgoing CLO will remain with the company as a senior advisor and an experienced in‑house general counsel will take over day‑to‑day CLO responsibilities immediately. For investors, the filing signals no abrupt departure from the company and no announced change to broader corporate strategy or financial guidance; it principally affects governance and legal leadership succession.